



Medical benefit specialty medication update bulletin – February 2025

Specialty medication program updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage and Individual & Family Plans

Updates to medication program requirements and drug policies							
Medication Name	HCPCS Code(s)	Effective Date	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	UHC Individual & Family	Summary of Changes
Kisunla™ (donanemab-azbt)	J0175	5/1/25		X Texas only			<ul style="list-style-type: none"> Add prior authorization/ notification
Pyzchiva® (ustekinumab-ttwe) <i>Biosimilar to Stelara®</i>	Q9997	5/1/25		X			<ul style="list-style-type: none"> Add prior authorization/ notification Add to Site of Care
Selarsdi™ (ustekinumab-aekn) <i>Biosimilar to Stelara</i>	Q9998	5/1/25		X			<ul style="list-style-type: none"> Add prior authorization/ notification Add to Site of Care
Wezlana™ (ustekinumab-auub) <i>Biosimilar to Stelara</i>	Q5138	5/1/25		X			<ul style="list-style-type: none"> Add prior authorization/ notification Add to Site of Care

UnitedHealthcare will honor all approved prior authorizations/notifications on file until the earlier of the end date on the authorization/notification or the date the member's eligibility changes. Upon prior authorization/notification renewal, the updated policy will apply.

Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230-RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization/notification is required. This exception does not apply to Medicaid and Medicare.

